First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer.

Timothy Anthony YapMaria VieitoCapucine BaldiniJuan Manuel Sepúlveda-SánchezShunsuke KondoMatteo SimonelliRasha CosmanAndre van der WesthuizenVictoria AtkinsonAntoine F CarpentierMario LöhrRebecca RedmanWarren MasonAndres CervantesEmilie Le RhunSebastian OchsenreitherLouise WarrenYumin ZhaoSophie CalliesShawn T EstremMichael ManLeena GandhiEmin AvsarDavide Melisi

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

LY3200882 as monotherapy and combination therapy was safe and well tolerated with preliminary antitumor activity observed in pancreatic cancer. Further studies to evaluate the efficacy of LY3200882 with gemcitabine and nab-paclitaxel in advanced pancreatic cancer are warranted.

Keyphrases

combination therapy
advanced cancer
palliative care
endothelial cells
clinical trial
transforming growth factor
induced pluripotent stem cells
pluripotent stem cells
advanced non small cell lung cancer
radiation therapy
open label
case control
study protocol